Skip to main contentSkip to navigation
Sirius Investors

STX.L Stock: Shield Therapeutics plc Stock Price, Analysis & Insights

Get live STX.L stock price $6.50, comprehensive Shield Therapeutics plc stock analysis, charts, news, and expert forecast. Real-time STX.L stock data and investment insights.

6.50
4.84%Today
STX.LShield Therapeutics plc • London Stock Exchange • Healthcare
Market Cap
69.52M
Volume
2.93M
52W High
12.50
52W Low
2.30

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Shield Therapeutics plc is a specialized pharmaceutical firm dedicated to developing and commercializing innovative drugs at various clinical stages to address significant unmet medical requirements. Their flagship product, Accrufer/Feraccru, is an o...

Company Information

CEO
Anders Lundstrom
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
63

Contact Information

Address
Northern Design Centre
Country
GB

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - Specialty & Generic

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.78)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Shield Therapeutics plc shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Shield Therapeutics plc
  • Investors should consider how Shield Therapeutics plc fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

69.52M

P/E Ratio (TTM)

-6.50

Beta

1.78

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.